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In 1999, two independent groups identiﬁed plasmacytoid dendritic cells (PDC) as major type I interferon- (IFN-) producing cells
in the blood. Since then, evidence is accumulating that PDC are a multifunctional cell population eﬀectively coordinating innate
and adaptive immune responses. This paper focuses on the role of diﬀerent immune cells and their interactions in the surveillance
ofalphaherpesvirusinfections,summarizescurrentknowledge onPDCsurfacereceptorsandtheirroleindirectcell-cellcontacts,
and develops a risk factor model for the clinical implications of herpes simplex and varicella zoster virus reactivation. Data from
studies involving knockout mice and cell-depletion experiments as well as human studies converge into a “spider web”, in which
the direct and indirect crosstalk between many cell populations tightly controls acute, latent, and recurrent alpha herpes virus
infections. Notably, cells involved in innate immune regulations appear to shape adaptive immune responses more extensively
than previously thought.
1.Introduction
The human alpha herpes viruses comprise three diﬀerent
viruses: herpes simplex virus type 1 (HSV-1), type 2 (HSV-
2 ) ,a n dv a r i c e l l az o s t e rv i r u s( V Z V )[ 1]. These highly
cytopathic viruses are characterized by a short replication
c y c l e ,ab r o a dc e l lt r o p i s m ,a n da ne ﬃcient spread in cell
culture. Importantly, they exhibit a distinct neurotropism,
which, after primary infection at mucocutaneous sites,
guides the viral particles along the peripheral sensory nerves
to the dorsal root ganglia or the trigeminal ganglion,
where they establish latent infection. Under circumstances of
local or systemic immune suppression, alpha herpes viruses
are reactivated and transported the same way, but in the
reverse direction, to the epithelial surfaces. Primary HSV-1
and HSV-2 infections can manifest as stomatitis aphthosa,
herpetic whitlow, and neonatal herpes acquired by passage
through the maternal birth canal [2]. Reactivations are well
known as cold sores, corneal, and genital herpes. Primary
and recurrent VZV infections manifest as chickenpox and
shingles, respectively [3]. In rare cases, alpha herpes viruses
cause severe diseases such as encephalitis, acute retinal
necrosis, and life-threatening systemic infections. It still
remains a mystery why only a few individuals in the large
cohort of seropositives are so severely aﬀected by these
viruses.
The ﬁrst animal model to investigate the pathogenesis
of acute, latent, and recurrent herpes viral infections was
described by von Szily, who, after inoculation of herpes
simplex virus into the anterior eye chamber of rabbits,
observed the spread of inﬂammation along the optic nerve
and inﬁltration of the uvea of the contralateral eye [4].
These results were conﬁrmed by Whittum and colleagues
in a mouse model [5], which paved the way for further
experimentsinwhichherpesviruspathogenesiswasanalyzed
in knockout mice or by depletion of individual cell popula-
tions.
The focus of this paper is the immune control of
alpha herpes virus infections. In particular, we wanted to
summarize the role of cells involved in innate and adaptive
immune responses and to highlight their interactions in
the eﬃcient control of acute and recurrent herpes virus2 Advances in Virology
CD8+ cyto-toxic
Tc e l l s
(CTL)
Myeloid
dendritic
cells (MDC)
γ-
δ
Tc e l l s
Plasmacytoid
dendritic cells
(PDC)
Kodukula 1999
Kodukula 1999
Liu 1996
Liu 1996
Sciammas 1997
Donaghy 2009
Donaghy 2009
Khanna 2003
Huch 2010
Barr 2007
Yoneyama 2005
Simmons 1992
Posavad 1996
Theil 2003
Minagawa 2000
Minagawa 2000
Liu 2000
Krug 2004
Azumi 1994
Azumi 1994
Tanigawa 2000
Verjans 2007
Gerlini 2006
Megjugorac 2007
Iijima 2008
Iijima 2008 Kittan 2007
Reading 2007
Johnson 2008
Lund 2006 Pollara 2004
Jirmo 2009
Mott 2009
Zhao 2003
Koelle 1998
Zhu 2007
Kassim 2006
Kassim 2009
Lee 2009
Schuster 2010
Deshpande 2000
Lund 2008
Adler 1999
Nandakumar 2008
Kassim 2006
Ashkar 2003
Grubor-Bauk 2003
Yuan 2006
Kastrukoff 2010
Nandakumar 2008
Mott 2008
Allan 2006
Kawamura 2006
Bosnjak 2005
Nishimura 2004 Fernandez 2008
Diaz 2006
Suvas 2004
Dudley 2000
Beland 1999
Kastrukoff 2010
Ashkar 2003
Lee 2009
Wakim 2008
Wakim 2008
Mott 2007
Suvas 2003
Milligan 2005
Iijima 2008
BenMohamed 2003
Ghiasi 1999
Kuklin 1998
Iijima 2008
Dobbs 2005
Parr 1998
Cathcart 2009
Milligan 2004
Koelle 1994, 1998
Mgjugorac 2004 Bosnjak 2005
Kassim 2006
Rajasagi 2009
Jirmo 2009
Kadowaki 2000
α
herpes
virus
Natural
killer cells
(NK)
CD4+
Tc e l l s
Macro-
phages
Regulatory
Tc e l l s( T r e g )
NK-T cells
(NK-T)
Bc e l l s
Figure 1: “Spider web” for the control of alpha herpes virus infections by cells of the innate and adaptive immune system (left and right side
of the ﬁgure, resp.).
infections with respect to the current literature. The reader is
also referred to excellent reviews by others which addressed
similar or related aspects of alpha herpes virus infections [6–
9]. The corresponding immune escape mechanisms of alpha
herpes viruses were recently described by others [10].
2.The Spider Web—ImmuneSurveillanceof
Alpha Herpes VirusInfections
The current literature on the control of acute and latent
h e r p e sv i r u si n f e c t i o n si ss u m m a r i z e di nFigure 1.T h e r ei s
not only evidence that single cell populations play a direct
role in the suppression of alpha herpes virus replication, but
cells interact with each other and across the innate-adaptive
barrier in mediating eﬃcient surveillance.
2.1. Innate Immune Control of Acute Herpes Virus Infections.
The resolution of acute herpes simplex infections is mostly
associatedwithmacrophagesandgammadeltaTcells.Liuand
colleagues detected both cell types inﬁltrating the trigeminal
ganglion after corneal HSV-1 infection in 1996 [11]. Mice
depleted of gamma delta T cells or macrophages suﬀered
from a more severe HSV-1 infection after footpad or ocular
inoculation [12, 13]. Similar ﬁndings were obtained when
the macrophage-derived inducible nitric oxide synthase was
inhibited, and tumor necrosis factor- (TNF-) alpha or
interferon- (IFN-) gamma secreted by macrophages and
gamma delta T cells, respectively, were neutralized [12].
Mice deﬁcient in gamma delta T cells were shown to be
susceptible to intravaginal HSV-2 infection [14]. Depletion
ofmacrophagesinimmunizedmiceincreasedthereplication
of HSV-1 in the eye of infected mice at early timepoints [15].
After injection of HSV-1 into the anterior eye chamber of
BALB/c mice, an early inﬂux of macrophages prevented the
spread to the ipsilateral retina [16].
A further case was made for the role of natural killer
(NK) and NK-T cells in the control of acute herpes simplex
virus infections. Thus, it was shown that mice lacking NK
and T cells suﬀered from more severe encephalitis after
intranasal HSV-1 inoculation compared to mice only lacking
T cells [17]. When HSV-1 was inoculated into the anterior
eye chamber of NK-depleted BALB/c mice, the virus rapidly
spread to the ispilateral retina [18]. Interleukin (IL-)18 was
shown to be involved in the rapid activation of NK cells and
thus in the control of early HSV-1 replication in the lung
afterintranasalinfectionofC57BL/6mice[19].NK-deﬁcient
mice also displayed a reduced quality and quantity of CD8+Advances in Virology 3
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Figure 2: Proposed model for the plasmacytoid dendritic cell (PDC) “life cycle”, which is based on the timely coordinated expression of
surface markers after contact with herpes simplex virus (HSV). The upper part of the ﬁgure depicts the attraction of PDC to inﬂamed tissue,
where they take up their antigen and interact with local eﬀector cells. Then, PDC reenter the blood stream and home to secondary lymphatic
tissue via high endothelial venules (HEV), where they shape the adaptive immune response via interaction with na¨ ıve T cells, as outlined at
the lower part of the ﬁgure.
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cytotoxic T lymphocytes (CTL), which deﬁnes a novel helper
roleforNKcells[20].C57BL/6micedeﬁcientinNKandNK-
TcellsweremoresusceptibletovaginalHSV-2infectionthan
control mice; these cells were the early source of IFN-gamma
in the vaginal ﬂuids [21]. In C57BL/6 mice lacking CD1d
or NK-T cells, the clearance of HSV-1 inoculated by skin
scariﬁcation was impaired compared to control mice [22].
These data are conﬁrmed by a study showing that HSV-1
evades NK-T cell recognition by suppressing CD1d recycling
[23]. The presence of NK-T cells, however, appeared to be
less critical, when a less virulent strain of HSV-1 was used for
infection [24].
2.2. Control of Herpes Virus Latency by Adaptive Immune
Responses. In a study published in 1994, the inoculation of
HSV-1 into the anterior eye chamber of BALB/c mice was
followed by the inﬁltration of the ipsi- and contralateral
retina after depletion of CD4+ and CD8+ T cells [25]. These
data were extended by others, reporting that CD4+ or CD8+
T cell functions were required for the clearance of HSV-1
from trigeminal ganglia and establishment of latent nonlytic
infection in mice [26]. In recurrent human genital HSV-
2 lesions, HSV-speciﬁc T cell clones were recovered, the
majority of which was positive for CD4 [27]. In a followup
study, the authors showed that the viral clearance from the
lesions was associated with a high level of local CD4+ and
CD8+ T cell cytolytic activities towards HSV-infected cells
[28].
S e v e r a lr e p o r t sf o c u so nCD4+ T cells as the major cell
population in the immune control of alpha herpes virus
infections. In a study using T cell subtype knockout mice
and mice depleted with T cell subset-speciﬁc antibodies,
immunity against vaginal HSV-2 challenge after vaccination
with recombinant vectors expressing viral glycoproteins was
dependent on CD4+ T cells [29]. Transfer of CD4+ T cells
(and to a minor extent CD8+ T cells) from immunized
BALB/cmiceintoseverecombinedimmunodeﬁcient(SCID)
mice contributed to latent HSV-1 infection in the trigeminal
ganglia [30]. Another group identiﬁed immunodominant
epitopes from the HSV-1 glycoprotein D that conferred
Th1 CD4+ T cell protective immunity against lethal ocu-
lar challenge in a mouse model [31]. In CD8+ T cell-
depleted and -deﬁcient mice, CD4+ T cells gradually cleared
infectious HSV-1 from neural tissues, not dependent on
perforin or Fas [32]. This mechanism was conﬁrmed in
another study, in which eﬀector CD4+ T cells protected mice
fromHSV-2infectionafterrecurrentvaginalchallenge,using
a noncytolytic mechanism via local IFN-gamma secretion
[33].
Various studies emphasize the role of CD8+ T cells in
controlling alpha herpes virus infections. In this respect,
CD8+ T cells were shown to be responsible for the clearance
of infectious HSV-1 virions from murine ganglia [34].
Mice depleted of CD4+ and CD8+ T cells, but also those
depleted of only CD8+ T cells, suﬀered from a more
severe HSV-2 infection in the vaginal epithelium than
nondepleted immune mice [35]. A high frequency of HSV-
speciﬁc CD8+ cytotoxic T cell precursors has been detected
in patients suﬀering from genital herpes [36]. Addition of
CD8alpha antibodies to ex vivo cultures of trigeminal ganglia
caused HSV-1 reactivation from latency as evident from
the expression of late proteins and infectious virions [37].
These data suggested ongoing viral replication at the sites
of herpes virus latency, which was conﬁrmed by detection
of viral transcripts of the ICP4 and thymidine kinase genes
in mouse ganglia [38, 39]. Others quantiﬁed the amount
of virus replication and reported about 500 neurons with
latency-associated transcripts in each trigeminal ganglion
compared to one neuron with early and late viral transcripts
and viral protein per 10 trigeminal ganglia [40]. Latent
HSV-1 infection in human trigeminal ganglia was shown
to be accompanied by a chronic inﬂammatory process [41],
and CD8+ T cells speciﬁc for an immunodominant HSV-1
glycoprotein B epitope could block HSV-1 reactivation from
latency in explanted trigeminal ganglion cultures [42]. The
mechanism was shown not to be dependent on perforin-
or Fas/FasL-mediated cytolytic pathways but on IFN-gamma
secretion [43, 44]. Herpes virus latency in human trigeminal
and genital ganglia was reported to be associated with
local, persistent T cell responses against HSV-1 and HSV-2,
respectively [45, 46]. The level of HSV-1 latency correlated
with higher levels of PD-1 mRNA, suggesting an exhaustion
of CD8+ T cells in the trigeminal ganglia of latently infected
mice [47]. Notably, recent data show a diminished CD8+
T cell response in the draining lymph nodes of CD4+ T
cell-depleted mice [48]. Altogether, CD4+ and CD8+ T cells
appear to play a major role in maintaining alpha herpes
virus latency by suppression of lytic replication. In neuronal
tissues, this control is mostly eﬀected through noncytotoxic
immune responses.
Belandandcolleaguesshowedin1999thatBcelldeﬁcient
mice succumbed to HSV-1 encephalitis compared to control
C57BL/6 mice and that the transfer of hyperimmune sera
protected from death [49]. SCID mice which were given
immune serum prior to corneal HSV-1 infection survived
withoutlatentinfection[30].InBcell-deﬁcientmice,vaginal
HSV-2 infection and spread was limited by the transfer
of immune sera [50], and the susceptibility to cutaneous
HSV infection was increased up to 1000-fold in BALB/c and
C57BL/6 mice with a defect in the μ-immunoglobulin chain
[51]. In addition, virus-speciﬁc plasma cells were found over
an extended period in sensory ganglia following intravaginal
HSV-2 inoculation, which may contribute to latency [52].
2.3. Modulation of Adaptive Immune Responses by Regulatory
TC e l l s(T r eg ) . The role of Treg in the control of alpha herpes
virus infections is controversiallydebated. Publications focus
on the suppressive role of Treg on CD4+ and CD8+ T cells
[53, 54]. Thus, enhanced CD8+ T cell responses and a lower
viral load were observed in mice depleted for Treg prior to
HSV-1 inoculation into the foot pad [54]. In a followup
study, a more severe immunoinﬂammatory stromal keratitis
was induced after HSV-1 inoculation into Treg-depleted
mice [55]. Another study reported enhanced CD8+ cell
cytotoxicity and IFN-gamma responses by CD4+ and CD8+
T cells as well as reduced viral titers in the draining lymph
nodes of Treg-depleted mice [56]. Into a diﬀerent direction
goes a recent report on Treg-depleted mice, which suﬀeredAdvances in Virology 5
from increased viral load and accelerated fatal infection after
vaginal HSV-2 inoculation, suggesting that Treg coordinate
early protective responses by allowing a timely entry of NK
cells, DC, and T cells into the infected tissue [57]. The
discovery of distinct surface markers of Treg, for example,
GARP, may facilitate further studies about the role of these
cells in controlling HSV infection [58].
2.4. Coordination of Innate and Adaptive Immunity by
Dendritic Cells (DC). There is ample evidence that myeloid
and plasmacytoid DC directly and indirectly contribute to
the control of alpha herpes virus infections. Mice which
were inoculated intravaginally with HSV-2 showed a rapid
recruitment of submucosal myeloid dendritic cells (MDC)
to the infected epithelium, which, presenting viral peptides
in the MHC class II context, emerged in the draining
lymph nodes and stimulated IFN-gamma secretion from
HSV-speciﬁc CD4+ T cells [59]. The binding of HSV-1
glycoprotein D caused type I IFN secretion and maturation
of MDC [60]. Others reported that HSV-infected apoptotic
DC were phagocytosed by uninfected bystander DC, which,
after cross-presentation of viral antigens, stimulated virus-
speciﬁc CD8+ T cells [61]. The depletion of CD11c+ DC
in the highly resistant C57BL/6 strain resulted in enhanced
susceptibilitytoHSV-1infectionandspreadintothenervous
system; the authors also observed an impaired activation of
NK cells, CD4+ and CD8+ T cells [62]. The viral antigen
appears to be taken up initially by migratory DC and
then transferred to lymphoid-resident DC for presentation
and CTL priming [63]. Immunization of mice with Flt3-
ligand DNA increased the number of CD11c+ CD8alpha+
DC and enhanced HSV-1 latency [64]. In extra-lymphoid
tissues, HSV-speciﬁc memory CD8+ T cell responses were
stimulated through a tripartite interaction withCD4+ Tcells
a n dD Cr e c r u i t e df r o mt h eb l o o d[ 65]. Dependent on the
mode of infection, lymph node-resident or tissue-derived
migratory DC pick up and present HSV-1 epitopes to CD4+
andCD8+Tcells[66].Recently,itwasshownthattheuptake
of virus released from target cells led to cross-presentation
of viral antigens, which was important for CTL immunity
in mice [67]. The cooperation of dendritic cells and B cells
restimulated memory CD4+ T cells to secrete IFN-gamma
[33], and the depletion of DC impaired the magnitude of
IFN-gamma expression and cytotoxicity of NK cells [68].
The importance of type I interferons has been high-
lighted in a study in which the expression of IFN-alpha in
astrocytes protected mice from acute and latent ocular HSV-
1 infection [69]. The type I IFN response of plasmacytoid
dendritic cells (PDC), the major producers of type I IFN, to
HSV-1ismediatedviatheToll-likereceptor(TLR)9/MyD88
pathway [70]. However, mice lacking MyD88 or TLR9 con-
trol HSV-1 replication, indicating that TLR9-independent
pathways are also involved [70, 71]. HSV-1 stimulation
of PDC, concomitant to IFN-alpha production, stimulated
na¨ ıve CD4+ T cells to produce IFN-gamma and IL-10 [72].
It also induced migration of activated T and NK cells by
production of the chemokines CCL4 and CXCL10 [73]. In a
mouse model of cutaneous HSV-1 infection, PDC-depleted
mice showed a reduced CD8+ T cell IFN-gamma production
and HSV-speciﬁc lysis accompanied by an increase in viral
load; PDC alone failed to induce CTL, however provided
eﬃcient help to lymph node dendritic cells [74]. In mice
vaginally inoculated with HSV-2, PDC were recruited to
the site of infection; PDC-depleted and TLR9-deﬁcient mice
had survival curves which were signiﬁcantly worse than
wild type mice [75]. In the human system, HSV-stimulated
PDC were shown to stimulate the diﬀerentiation of na¨ ıve
CD4+ T cells into cytotoxic “regulatory” T cells, which
expressed perforin and granzymes, and produced IFN-
gamma and IL-10 [76]. Another group reported that PDC-
derived IL-18 rapidly activated NK cells in HSV-1 infection
[77]. Human PDC were recruited to varicella skin lesions
[78, 79], and inﬁltrated the dermis of recurrent genital
herpes simplex lesions, closely associated with NK and T
cells[80].HSV-infectedmonocyte-derivedDCinducedIFN-
alpha production in PDC through the exchange of cellular
material [81]. We have reported reduced PDC counts and
function together with reduced CD8+ T cell IFN-gamma
production in patients with HSV- and VZV-associated acute
retinal necrosis [82]. However, it remained unclear whether
these deﬁcits were cause or consequence of uncontrolled
virus replication. Altogether, evidence is accumulating that
PDC are directly and indirectly involved in the control of
acute and latent alpha herpes virus infections.
3. The PDC “Life Cycle”—A Reﬂection of
the Surface Receptor Repertoire
What is the evidence that PDC—in addition to secretion
of type I IFN and proinﬂammatory cytokines—shape the
immune response by direct cell-cell contact? The antigen-
presenting properties of PDC, which we are just beginning
to understand, were recently addressed in an excellent review
[83]. The PDC surface receptors are increasingly coming
into the focus of scientiﬁc research [84–88]. However, data
about the function of PDC surface receptors in alpha herpes
virus infections are scarce, and in most cases the function is
deduced from the regulation of expression upon stimulation
of PDC with HSV, other viruses or CpG, and from the
function of these surface receptors on other cell populations.
Having these caveats in mind, we propose a model
of the PDC “life cycle” (Figure 2), which was originally
developed from chip and ﬂow cytometry analyses of PDC in
response to HSV-1 [87]. The timely coordinated regulation
of PDC surface receptors suggests an inﬂammatory migra-
tion proﬁle similar to gamma delta T cells [89], in which
PDC are attracted to the site of infection, encounter their
cognate antigen, reenter the blood stream, and then migrate
to secondary lymphatic tissue. In more detail, immature
PDC express three receptors for proinﬂammatory cytokines
(CD183, CD184, and CD195), which were shown to be
functional on these cells [90–92]. The presence of receptors
involved in adhesion and rolling at the vascular endothelium
(CD31, CD43, CD44, CD47, CD62L, CD99, and CD162)
and those mediating ﬁrm adhesion and transmigration
(CD11a, CD18, CD29, and CD49d) [93] suggest that PDC
are recruited to inﬂamed tissue; explicit evidence is available6 Advances in Virology
for CD31 [92]. These data are corroborated by the detection
of PDC in HSV and VZV lesions [75, 78–80]. At the site
of infection, uptake of antigen may be mediated by three
herpes virus entry mediators, namely CD111 (HVE-C),
CD112 (HVE-B), and CD270 (HVE-A, HVEM) [80]. Other
receptors relevant for antigen uptake may be CD4, the C-
type lectin BDCA2 (CD303) [94, 95], Fc receptors [96–98],
and CD170 (Siglec-5) [99]. Subsequent PDC activation and
maturation can be seen from the enhanced expression of
CD38, CD69, and CD83. Concomitant downregulation of
adhesion molecules suggests that PDC can emigrate from
the site of infection and reenter the blood stream. Homing
to lymphatic tissue appears to be mediated by CD62L (L-
selectin) [93, 100–102] and enhanced expression of the CC
chemokine receptor 7 (CD197), which binds to CCL19 and
CCL21expressedbyhighendothelialvenulesinlymphnodes
[90, 91, 103, 104]. Upon HSV-1 stimulation, CD197 was
one of the few receptors which were upregulated with delay
[87], suggesting that PDC indeed migrate from the site of
infection to secondary lymphatic tissue. However, it has not
been formally excluded that two diﬀerent PDC populations
migrate to diﬀerent localizations.
The model of the PDC “life cycle” proposes two sites
of interaction with other cells of the immune system: the
inﬂamed tissue where PDC may encounter eﬀector cells,
and the lymphatic tissue, where PDC may interact with
na¨ ıve cells and shape adaptive immune responses by the
expression of coregulatory surface molecules. At the site of
infection, expression of the SLAM family members CD48,
CD229 (LY9), CD319 (CRACC), and CD352 (NTBA) may
beparticularlyimportantfortheinteractionofPDCwithNK
and T cells [85, 87, 105–109]. CD319 may also induce prolif-
erationofBcells[110].Thiscrosstalkappearstobemediated
predominantly via homotypic receptor interactions [111].
Interaction of PDC with eﬀector cells may also be inﬂu-
enced by the TNF receptor family [112]. PDC stimulated
by virus or CpG express the ligand for the glucocorticoid-
induced tumor necrosis factor receptor (GITRL), which may
promote cytotoxicity and IFN-gamma production of CD357
(GITR)-expressing NK and T cells [113]. CpG-stimulated
PDC fully activated NK-T cells involving direct contact
of CD252 (OX40L) and CD134 (OX40) [114, 115]. CpG-
activated PDC were also shown to promote B cell diﬀerentia-
tion and immunoglobulin secretion via interaction of CD70
with CD27 [116].
A third family mediating coregulatory signals for na¨ ıve
and memory T cells are the CD28 family ligands [112]. Of
these, CD80, CD86, CD270, CD274 (B7-H1, PD-L1), and
CD275 (B7-H2, ICOS-L) were described to be expressed
on the PDC surface [80, 93, 95, 100, 117]. CpG- or
HSV-stimulated PDC appear to drive CD4+ Treg immune
responses via CD275 [117, 118], whereas CD40L-exposed
PDC promoted the proliferation of CD8+ Treg [119].
CD50, CD54, and CD229 were reported to play an
important role in the immunological synapse [120, 121],
whereas the role of BDCA4 is still controversially discussed
[122, 123]. PDC express the costimulatory molecules CD58
and CD97, which may costimulate NK and T cells [93, 124–
126]. TLR9-activated PDC express the lectin-like transcript
1 (LLT1, CLEC2D), which interacts with CD161 on NK and
eﬀector T cells [127]. Recognition of virus-infected cells with
subsequent induction of apoptotic and cytotoxic immune
responses may be mediated by the enhanced expression of
TRAIL (CD253) [128–130].
Several publications provide evidence for direct antigen
presentation by PDC. After internalization and processing
of inﬂuenza viruses, PDC cross-presented these antigens
on MHC class I to CD8+ T cells [131]. Cross-priming
of na¨ ıve CD8+ T cells with ovalbumin-exposed PDC was
dependent on concomitant TLR activation [132]. Endo-
cytosis of cytomegalovirus antigen together with CpG-B
enhancedvirus-speciﬁcmemoryCD4+Tcellresponses[95].
In contrast, Yoneyama reported an indirect eﬀect of PDC on
the induction of CD8+ CTL by providing eﬃcient help to
lymphnodeDCviaCD2andCD40Linamodelofcutaneous
HSV-1 infection [74]. In addition, inﬁltrating CD8+ T
cells may reciprocally inﬂuence PDC immune responses by
secretion of IL-3 [133], which contributes to maturation and
survival of PDC [100, 117].
4.The RiskFactorModel—Clinical
ImplicationsofHerpesVirusReactivation
One of the best studied models of alpha herpes virus
reactivation from latency is the acute retinal necrosis (ARN).
Roughly one and two thirds of cases are caused by reac-
tivation of HSV and VZV, respectively. Clinical course,
treatment options and therapy outcome of this severe disease
were recently reviewed [134–136]. The vasculitis, retinal
necrosis, and intraocular inﬂammation start in the periph-
ery and rapidly progress circumferentially, mostly aﬀecting
nonimmunocompromised patients at a frequency of 0.5
cases per 1 million. Current therapies combine antiviral
and anti-inﬂammatory drugs with surgical intervention. An
early vitrectomy with silicon oil instillation is associated
with a lower incidence of retinal detachment compared to
conservative treatment; however, the overall visual prognosis
is poor [137, 138]. The cause appears to be, besides retinal
detachment, herpes virus-associated retinal ischemia and
atrophy of the optic nerve [139].
In patients suﬀering from herpes virus-associated ARN,
severalriskfactorscanbeidentiﬁed(Figure 3).Assuch,there
are previous ARN or chorioretinal scars from other diseases,
for example, toxoplasmosis; periocular trauma; ocular; or
brainsurgery;previousherpessimplexvirusencephalitisand
iatrogenic or acquired immune deﬁciency caused by corti-
coid and/or antineoplastic treatment and HIV-1 infection,
respectively [140–142]. In a systemic survey of nine patients
with ARN, we additionally identiﬁed meningitis/encephalitis
and frequent infections in childhood, recurrent herpes virus
aﬀections at unusual localizations in patients and relatives,
as well as (bacterial) infections and stress around ARN [82].
These factors point to a local break in the integrity of ocular
tissues and a weakened immune system distracted by other
challenges.
In addition, one may propose an (unknown) selective
defect in the innate or adaptive immunity, which predisposesAdvances in Virology 7
to alpha herpes virus reactivation. In mice, TLR9 plays a
major role for the recognition of HSV-1 and HSV-2 although
TLR-independent pathways have been described [70, 143].
Knockout mice for TLR2 and TLR9 were shown to be more
susceptible to HSV-1 encephalitis [144, 145]. Similarly, the
interferon response factor 3, which is in the downstream
signaling cascade of endosomal and cytosolic recognition
factors for double-stranded RNA, plays an important role
in the control of HSV-1 replication [146, 147]. In humans,
TLR9 is expressed on PDC and B cells, but—unlike the
murinesystem—notonmyeloidDC,whichmayexplainwhy
s e v e r ea l p h ah e r p e sv i r u si n f e c t i o n sh a v en o tb e e na s s o c i a t e d
with TLR9 polymorphisms in humans. Instead, defects in
STAT1 [148], TLR3 [149], and the endoplasmatic reticu-
lum transmembrane protein UNC93B have been reported
in patients suﬀering from herpes simplex virus-associated
encephalitis [150, 151].
5. Conclusions
What have we learned from the published data? General
conclusions are shortened in terms of the variability of ani-
mal models used: diﬀerent animal strains, diﬀerent viruses,
and diﬀerent modes of infection may lead to diﬀerent
conclusions.Anothercaveatisthatmousedatadonotreadily
translate into the human system, for which the data are
still limited. Yet, three important conclusions can be drawn.
First, many cell populations are involved to keep primary
and recurrent alpha herpes virus infections under control,
which may reﬂect how seriously these cytopathic infections
are taken by the immune system. A second conclusion
is that the textbook knowledge of innate cells controlling
primary infection and adaptive immunity supervising latent
alpha herpes virus infections is no longer clearcut. Cells
involved in innate immune regulations appear to shape
adaptiveimmuneresponsesmoreextensivelythanpreviously
thought. Is there a master regulator in this system, for
example, the two dendritic cell populations that coordinate
each other and all other cells ? Or does each component
of the immune system substitute for another in some
respect ? A third conclusion is that interactions of diﬀerent
cell populations via soluble factors and in particular via
surface receptors appear to be crucial to ﬁght against alpha
herpes virus infections [152, 153], which, if not controlled
eﬃciently, will cause severe disabling diseases.
Abbreviations
ARN: Acute retinal necrosis
CCR: CC chemokine receptor
CTL: Cytotoxic T lymphocytes
DC: Dendritic cells
HSV: Herpes simplex virus
IFN: Interferon
IL: Interleukin
L: Ligand
MDC: Myeloid dendritic cells
NK: Natural killers
PDC: Plasmacytoid dendritic Cells
SCID: Severe combined immunodeﬁciency
TLR: Toll-like receptor
TNF: Tumor necrosis factor
Treg: Regulatory T cells
VZV: Varicella zoster virus.
Acknowledgments
The authors thank Bernhard Fleckenstein for continuous
support. P. Schuster, J. B. Boscheinen, and K. Tennert were
supported by the graduate college 1071 (“Viruses of the
Immune System”, Project B5). They acknowledge fund-
ing by the German Research Foundation (SCHM1702/2-1,
SCHM1702/2-2, and SCHM1702/3-1) and the “Akademie
der Wissenschaften und Literatur zu Mainz”. They apologize
to all appreciated colleagues whose data they may have
overlooked.
Conﬂict of Interests
The authors have no ﬁnancial conﬂict of interests.
References
[1] P. E. Pellett and B. Roizman, “The family Herpesviridae: a
brief introduction,” in Fields Virology, D. M. Knipe and P. M.
Howley,Eds.,pp.2479–2499,LippincottWilliams&Wilkins,
2007.
[2] B. Roizman, D. M. Knipe, and R. J. Whitley, “Herpes simplex
viruses,” in Fields Virology, D. M. Knipe and P. M. Howley,
Eds., pp. 2501–2601, Lippincott Williams & Wilkins, 2007.
[ 3 ]J .I .C o h e n ,S .E .S t r a u s ,a n dA .M .A r v i n ,“ V a r i c e l l a - z o s t e r
virus,”inFieldsVirology,D.M.KnipeandP.M.Howley,Eds.,
pp. 2773–2818, Lippincott Williams & Wilkins, 2007.
[4] A. V. von Szily, “An experimental endogenous transmission
of infection from bulbus to bulbus,” Klinische Monatsblatter
fur Augenheilkunde, vol. 75, pp. 593–602, 1924.
[5] J. A. Whittum, J. P. McCulley, J. Y. Niederkorn, and J.
W. Streilein, “Ocular disease induced in mice by anterior
chamber inoculation of herpes simplex virus,” Investigative
Ophthalmology and Visual Science, vol. 25, no. 9, pp. 1065–
1073, 1984.
[6] V. Decman, M. L. Freeman, P. R. Kinchington, and R.
L. Hendricks, “Immune control of HSV-1 latency,” Viral
Immunology, vol. 18, no. 3, pp. 466–473, 2005.
[7] K. M. Khanna, A. J. Lepisto, V. Decman, and R. L. Hendricks,
“Immune control of herpes simplex virus during latency,”
Current Opinion in Immunology, vol. 16, no. 4, pp. 463–469,
2004.
[8] G. R. Van De Walle, E. Cox, H. Nauwynck, and H. W.
Favoreel, “The role of dendritic cells in alphaherpesvirus
infections: archetypes and paradigms,” Reviews in Medical
Virology, vol. 19, no. 6, pp. 338–358, 2009.
[9] D. M. Koelle and L. Corey, “Herpes simplex: insights
on pathogenesis and possible vaccines,” Annual Review of
Medicine, vol. 59, pp. 381–395, 2008.
[10] B. D. Griﬃn ,M .C .V e r w e i j ,a n dE .J .H .J .W i e r t z ,
“Herpesviruses and immunity: the art of evasion,” Veterinary
Microbiology, vol. 143, no. 1, pp. 89–100, 2010.
[11] T. Liu, Q. Tang, and R. L. Hendricks, “Inﬂammatory
inﬁltration of the trigeminal ganglion after herpes simplex8 Advances in Virology
virus type 1 corneal infection,” Journal of Virology, vol. 70,
no. 1, pp. 264–271, 1996.
[ 1 2 ]P .K o d u k u l a ,T .L i u ,N .V a nR o o i j e n ,M .J .J a g e r ,a n dR .
L. Hendricks, “Macrophage control of herpes simplex virus
type 1 replication in the peripheral nervous system,” Journal
of Immunology, vol. 162, no. 5, pp. 2895–2905, 1999.
[13] R.Sciammas,P.Kodukula,Q.Tang,R.L.Hendricks,andJ.A.
Bluestone, “T cell receptor-γ/δ cells protect mice from herpes
simplex virus type 1-induced lethal encephalitis,” Journal of
ExperimentalMedicine,vol.185,no.11,pp.1969–1975,1997.
[14] H. Nishimura, T. Yajima, Y. Kagimoto et al., “Intraepithelial
γδ T cells may bridge a gap between innate immunity and
acquired immunity to herpes simplex virus type 2,” Journal
of Virology, vol. 78, no. 9, pp. 4927–4930, 2004.
[ 1 5 ]K .M o t t ,D .J .B r i c k ,N .V a nR o o i j e n ,a n dH .G h i a s i ,
“Macrophages are important determinants of acute ocular
HSV-1 infection in immunized mice,” Investigative Ophthal-
mology and Visual Science, vol. 48, no. 12, pp. 5605–5615,
2007.
[ 1 6 ]H .M .C a t h c a r t ,M .A .F i e l d s ,M .Z h e n g ,B .M a r s h a l l ,a n dS .
S. Atherton, “Inﬁltrating cells and IFNγ production in the
injected eye after uniocular anterior chamber inoculation of
HSV-1,” Investigative Ophthalmology and Visual Science, vol.
50, no. 5, pp. 2269–2275, 2009.
[17] H. Adler, J. L. Beland, N. C. Del-Pan, L. Kobzik, R. A. Sobel,
and I. J. Rimm, “In the absence of T cells, natural killer cells
protect from mortality due to HSV-1 encephalitis,” Journal of
Neuroimmunology, vol. 93, no. 1-2, pp. 208–213, 1999.
[ 1 8 ]M .T a n i g a w a ,J .E .B i g g e r ,M .Y .K a n t e r ,a n dS .S .A t h e r t o n ,
“Natural killer cells prevent direct anterior-to-posterior
spread of herpes simplex virus type I in the eye,” Investigative
OphthalmologyandVisualScience,vol.41,no.1,pp.132–137,
2000.
[19] P. C. Reading, P. G. Whitney, D. P. Barr et al., “IL-18, but not
IL-12, regulates NK cell activity following intranasal herpes
simplex virus type 1 infection,” Journal of Immunology, vol.
179, no. 5, pp. 3214–3221, 2007.
[20] S. Nandakumar, S. N. Woolard, D. Yuan, B. T. Rouse, and
U. Kumaraguru, “Natural killer cells as novel helpers in anti-
herpes simplex virus immune response,” Journal of Virology,
vol. 82, no. 21, pp. 10820–10831, 2008.
[21] A. A. Ashkar and K. L. Rosenthal, “Interleukin-15 and natu-
ralkillerandNKTcellsplayacriticalroleininnateprotection
against genital herpes simplex virus type 2 infection,” Journal
of Virology, vol. 77, no. 18, pp. 10168–10171, 2003.
[22] B.Grubor-Bauk,A.Simmons,G.Mayrhofer,andP.G.Speck,
“Impairedclearanceofherpessimplexvirustype1frommice
lacking CD1d or NKT cells expressing the semivariant Vα14-
Jα281TCR,”JournalofImmunology,vol.170,no.3,pp.1430–
1434, 2003.
[23] W. Yuan, A. Dasgupta, and P. Cresswell, “Herpes simplex
virus evades natural killer T cell recognition by suppressing
CD1d recycling,” Nature Immunology, vol. 7, no. 8, pp. 835–
842, 2006.
[24] A. L. Cornish, R. Keating, K. Kyparissoudis, M. J. Smyth, F.
R. Carbone, and D. I. Godfrey, “NKT cells are not critical for
HSV-1 disease resolution,” Immunology and Cell Biology, vol.
84, no. 1, pp. 13–19, 2006.
[25] A.Azumi andS. S.Atherton,“Sparing oftheipsilateral retina
after anterior chamber inoculation of HSV-1: requirement
foreitherCD4+ orCD8+ Tcells, ”InvestigativeOphthalmology
and Visual Science, vol. 35, no. 8, pp. 3251–3259, 1994.
[26] H. Ghiasi, G. C. Perng, A. B. Nesburn, and S. L. Wechsler,
“Either a CD4+ or CD8+ T cell function is suﬃcient for
clearance of infectious virus from trigeminal ganglia and
establishmentofherpessimplexvirustype1latencyinmice,”
Microbial Pathogenesis, vol. 27, no. 6, pp. 387–394, 1999.
[ 2 7 ]D .M .K o e l l e ,H .A b b o ,A .P e c k ,K .Z i e g w e i d ,a n dL .C o r e y ,
“Direct recovery of herpes simplex virus (HSV)-speciﬁc T
lymphocyte clones from recurrent genital HSV-2 lesions,”
Journal of Infectious Diseases, vol. 169, no. 5, pp. 956–961,
1994.
[ 2 8 ]D .M .K o e l l e ,C .M .P o s a v a d ,G .R .B a r n u m ,M .L .J o h n s o n ,
J. M. Frank, and L. Corey, “Clearance of HSV-2 from
recurrent genital lesions correlates with inﬁltration of HSV-
speciﬁc cytotoxic T lymphocytes,” The Journal of Clinical
Investigation, vol. 101, no. 7, pp. 1500–1508, 1998.
[29] N. A. Kuklin, M. Daheshia, S. Chun, and B. T. Rouse, “Role
of mucosal immunity in herpes simplex virus infection,”
JournalofImmunology, vol.160,no.12,pp.5998–6003, 1998.
[30] H. Minagawa and Y. Yanagi, “Latent herpes simplex virus-
1 infection in SCID mice transferred with immune CD4+T
cells: a new model for latency,” Archives of Virology, vol. 145,
no. 11, pp. 2259–2272, 2000.
[31] L. BenMohamed, G. Bertrand, C. D. McNamara et al., “Iden-
tiﬁcation of novel immunodominant CD4+ Th1-type T-cell
peptide epitopes from herpes simplex virus glycoprotein D
that confer protective immunity,” Journal of Virology, vol. 77,
no. 17, pp. 9463–9473, 2003.
[32] A. J. Johnson, C. F. Chu, and G. N. Milligan, “Eﬀector CD4+
T-cell involvement in clearance of infectious herpes simplex
virus type 1 from sensory ganglia and spinal cords,” Journal
of Virology, vol. 82, no. 19, pp. 9678–9688, 2008.
[33] N. Iijima, M. M. Linehan, M. Zamora et al., “Dendritic cells
and B cells maximize mucosal Th1 memory response to
herpes simplex virus,” Journal of Experimental Medicine, vol.
205, no. 13, pp. 3041–3052, 2008.
[34] A. Simmons and D. C. Tscharke, “Anti-CD8 impairs clear-
ance of herpes simplex virus from the nervous system:
Implications for the fate of virally infected neurons,” Journal
of Experimental Medicine, vol. 175, no. 5, pp. 1337–1344,
1992.
[35] M. B. Parr and E. L. Parr, “Mucosal immunity to herpes
simplex virus type 2 infection in the mouse vagina is
impaired by in vivo depletion of T lymphocytes,” Journal of
Virology, vol. 72, no. 4, pp. 2677–2685, 1998.
[36] C. M. Posavad, D. M. Koelle, and L. Corey, “High frequency
ofCD8cytotoxicT-lymphocyteprecursorsspeciﬁcforherpes
simplex viruses in persons with genital herpes,” Journal of
Virology, vol. 70, no. 11, pp. 8165–8168, 1996.
[37] T. Liu, K. M. Khanna, X. Chen, D. J. Fink, and R. L.
Hendricks,“CD8+ Tcellscanblockherpessimplexvirustype
1 (HSV-1) reactivation from latency in sensory neurons,”
Journal of Experimental Medicine, vol. 191, no. 9, pp. 1459–
1466, 2000.
[38] S. H. Chen, M. F. Kramer, P. A. Schaﬀer, and D. M. Coen,
“A viral function represses accumulation of transcripts from
productive-cycle genes in mouse ganglia latently infected
with herpes simplex virus,” Journal of Virology, vol. 71, no.
8, pp. 5878–5884, 1997.
[39] M. F. Kramer and D. M. Coen, “Quantiﬁcation of transcripts
from the ICP4 and thymidine kinase genes in mouse ganglia
latently infected with herpes simplex virus,” Journal of
Virology, vol. 69, no. 3, pp. 1389–1399, 1995.
[40] L. T. Feldman, A. R. Ellison, C. C. Voytek, L. Yang, P. Krause,
and T. P. Margolis, “Spontaneous molecular reactivation of
herpes simplex virus type 1 latency in mice,” ProceedingsAdvances in Virology 9
of the National Academy of Sciences of the United States of
America, vol. 99, no. 2, pp. 978–983, 2002.
[41] D. Theil, T. Derfuss, I. Paripovic et al., “Latent herpesvirus
infection in human trigeminal ganglia causes chronic
immune response,” American Journal of Pathology, vol. 163,
no. 6, pp. 2179–2184, 2003.
[42] K. M. Khanna, R. H. Bonneau, P. R. Kinchington, and R. L.
Hendricks, “Herpes simplex virus-speciﬁc memory CD8+ T
cells are selectively activated and retained in latently infected
sensory ganglia,” Immunity, vol. 18, no. 5, pp. 593–603, 2003.
[43] M. E. Dobbs, J. E. Strasser, C. F. Chu, C. Chalk, and G. N.
Milligan, “Clearance of herpes simplex virus type 2 by CD8+
Tcellsrequiresgammainterferonandeitherperform-orFas-
mediated cytolytic mechanisms,” Journal of Virology, vol. 79,
no. 23, pp. 14546–14554, 2005.
[44] G. N. Milligan, K. L. Dudley-McClain, C. G. Young, and C.
F. Chu, “T-cell-mediated mechanisms involved in resolution
of genital herpes simplex virus type 2 (HSV-2) infection of
mice,” Journal of Reproductive Immunology,v o l .6 1 ,n o .2 ,p p .
115–127, 2004.
[45] G. M. G. M. Verjans, R. Q. Hintzen, J. M. Van Dun et al.,
“Selective retention of herpes simplex virus-speciﬁc T cells
in latently infected human trigeminal ganglia,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 104, no. 9, pp. 3496–3501, 2007.
[46] J.Zhu,D.M.Koelle,J.Caoetal.,“Virus-speciﬁcCD8+ Tc ells
accumulate near sensory nerve endings in genital skin during
subclinical HSV-2 reactivation,” Journal of Experimental
Medicine, vol. 204, no. 3, pp. 595–603, 2007.
[47] K. R. Mott, C. J. Bresee, S. J. Allen, L. BenMohamed, S.
L. Wechsler, and H. Ghiasi, “Level of herpes simplex virus
type 1 latency correlates with severity of corneal scarring and
exhaustion of CD8+ T cells in trigeminal ganglia of latently
infected mice,” Journal of Virology, vol. 83, no. 5, pp. 2246–
2254, 2009.
[48] N. K. Rajasagi, S. H. Kassim, C. M. Kollias, X. Zhao, R.
Chervenak, and S. R. Jennings, “CD4+ Tcells arerequired for
the priming of CD8 T cells following infection with herpes
simplex virus type 1,” Journal of Virology, vol. 83, no. 10, pp.
5256–5268, 2009.
[49] J. L. Beland, R. A. Sobel, H. Adler, N. C. Del-Pan, and I. J.
Rimm, “B cell-deﬁcient mice have increased susceptibility to
HSV-1encephalomyelitisandmortality,”JournalofNeuroim-
munology, vol. 94, no. 1-2, pp. 122–126, 1999.
[50] K. L. Dudley, N. Bourne, and G. N. Milligan, “Immune
protection against HSV-2 in B-cell-deﬁcient mice,” Virology,
vol. 270, no. 2, pp. 454–463, 2000.
[51] S. P. Deshpande, U. Kumaraguru, and B. T. Rouse, “Dual
role of B cells in mediating innate and acquired immunity
toherpessimplexvirusinfections,”CellularImmunology,vol.
202, no. 2, pp. 79–87, 2000.
[52] G. N. Milligan, M. G. Meador, C. F. Chu, C. G. Young, T.
L. Martin, and N. Bourne, “Long-term presence of virus-
speciﬁc plasma cells in sensory ganglia and spinal cord
following intravaginal inoculation of herpes simplex virus
type 2,” Journal of Virology, vol. 79, no. 17, pp. 11537–11540,
2005.
[53] G. A. Diaz and D. M. Koelle, “Human CD4+ CD25 high
cells suppress proliferative memory lymphocyte responses to
herpes simplex virus type 2,” Journal of Virology, vol. 80, no.
16, pp. 8271–8273, 2006.
[54] S. Suvas, U. Kumaraguru, C. D. Pack, S. Lee, and B. T.
Rouse, “CD4+CD25+ T cells regulate virus-speciﬁc primary
and memory CD8+ T cell responses,” Journal of Experimental
Medicine, vol. 198, no. 6, pp. 889–901, 2003.
[55] S. Suvas, A. K. Azkur, B. S. Kim, U. Kumaraguru, and B. T.
Rouse, “CD4+CD25+ regulatoryTcellscontroltheseverityof
viral immunoinﬂammatory lesions,” Journal of Immunology,
vol. 172, no. 7, pp. 4123–4132, 2004.
[56] M. A. Fernandez, F. K. Puttur, Y. M. Wang, W. Howden, S.
I. Alexander, and C. A. Jones, “T regulatory cells contribute
to the attenuated primary CD8+ and CD4+ T cell responses
to herpes simplex virus type 2 in neonatal mice,” Journal of
Immunology, vol. 180, no. 3, pp. 1556–1564, 2008.
[57] J. M. Lund, L. Hsing, T. T. Pham, and A. Y. Rudensky,
“Coordinationofearlyprotectiveimmunitytoviralinfection
by regulatory T cells,” Science, vol. 320, no. 5880, pp. 1220–
1224, 2008.
[58] R. Wang, L. Kozhaya, F. Mercer, A. Khaitan, H. Fujii, and
D. Unutmaz, “Expression of GARP selectively identiﬁes
activated human FOXP3+ regulatory T cells,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 106, no. 32, pp. 13439–13444, 2009.
[59] X. Zhao, E. Deak, K. Soderberg et al., “Vaginal submucosal
dendritic cells, but not langerhans cells, induce protective
Th1 responses to herpes simplex virus-2,” Journal of Exper-
imental Medicine, vol. 197, no. 2, pp. 153–162, 2003.
[60] G. Pollara, M. Jones, M. E. Handley et al., “Herpes simplex
virus type-1-induced activation of myeloid dendritic cells:
the roles of virus cell interaction and paracrine type I IFN
secretion,” Journal of Immunology, vol. 173, no. 6, pp. 4108–
4119, 2004.
[61] L. Bosnjak, M. Miranda-Saksena, D. M. Koelle, R. A. Boadle,
C. A. Jones, and A. L. Cunningham, “Herpes simplex virus
infection of human dendritic cells induces apoptosis and
allows cross-presentation via uninfected dendritic cells,”
Journal of Immunology, vol. 174, no. 4, pp. 2220–2227, 2005.
[62] S. H. Kassim, N. K. Rajasagi, X. Zhao, R. Chervenak, and S.
R. Jennings, “In vivo ablation of CD11c-positive dendritic
cells increases susceptibility to herpes simplex virus type 1
infection and diminishes NK and T-cell responses,” Journal
of Virology, vol. 80, no. 8, pp. 3985–3993, 2006.
[63] R. S. Allan, J. Waithman, S. Bedoui et al., “Migratory
dendriticcellstransferantigentoalymphnode-residentden-
dritic cell population for eﬃcient CTL priming,” Immunity,
vol. 25, no. 1, pp. 153–162, 2006.
[64] K. R. Mott, D. Underhill, S. L. Wechsler, and H. Ghi-
asi, “Lymphoid-related CD11c+ CD8α+ dendritic cells are
involved in enhancing herpes simplex virus type 1 latency,”
Journal of Virology, vol. 82, no. 20, pp. 9870–9879, 2008.
[65] L. M. Wakim, J. Waithman, N. Van Rooijen, W. R. Heath,
and F. R. Carbone, “Dendritic cell-induced memory T cell
activation in nonlymphoid tissues,” Science, vol. 319, no.
5860, pp. 198–202, 2008.
[66] H. K. Lee, M. Zamora, M. M. Linehan et al., “Diﬀerential
roles of migratory and resident DCs in T cell priming after
mucosal or skin HSV-1 infection,” Journal of Experimental
Medicine, vol. 206, no. 2, pp. 359–370, 2009.
[67] A. C. Jirmo, C. H. Nagel, C. Bohnen, B. Sodeik, and G. M.
N. Behrens, “Contribution of direct and cross-presentation
to CTL immunity against herpes simplex virus 1,” Journal of
Immunology, vol. 182, no. 1, pp. 283–292, 2009.
[68] S. H. Kassim, N. K. Rajasagi, B. W. Ritz et al., “Dendritic cells
are required for optimal activation of natural killer functions
following primary infection with herpes simplex virus type
1,” Journal of Virology, vol. 83, no. 7, pp. 3175–3186, 2009.10 Advances in Virology
[69] D. J. J. Carr, L. A. Veress, S. Noisakran, and I. L. Campbell,
“Astrocyte-targeted expression of IFN-α1 protects mice from
acute ocular herpes simplex virus type 1 infection,” Journal of
Immunology, vol. 161, no. 9, pp. 4859–4865, 1998.
[ 7 0 ]A .K r u g ,G .D .L u k e r ,W .B a r c h e t ,D .A .L e i b ,S .A k i r a ,a n d
M. Colonna, “Herpes simplex virus type 1 activates murine
natural interferon-producing cells through toll-like receptor
9,” Blood, vol. 103, no. 4, pp. 1433–1437, 2004.
[71] H.Hochrein,B.Schlatter,M.O’Keeﬀeetal.,“Herpessimplex
virus type-1 induces IFN-α production via Toll-like receptor
9-dependent and -independent pathways,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 101, no. 31, pp. 11416–11421, 2004.
[72] N. Kadowaki, S. Antonenko, J. Y. N. Lau, and Y. J. Liu,
“Natural interferon α/β-producing cells link innate and
adaptive immunity,” Journal of Experimental Medicine, vol.
192, no. 2, pp. 219–225, 2000.
[73] N. J. Megjugorac, H. A. Young, S. B. Amrute, S. L. Olshalsky,
and P. Fitzgerald-Bocarsly, “Virally stimulated plasmacytoid
dendritic cells produce chemokines and induce migration of
T and NK cells,” Journal of Leukocyte Biology, vol. 75, no. 3,
pp. 504–514, 2004.
[74] H. Yoneyama, K. Matsuno, E. Toda et al., “Plasmacytoid DCs
help lymph node DCs to induce anti-HSV CTLs,” Journal of
Experimental Medicine, vol. 202, no. 3, pp. 425–435, 2005.
[75] J. M. Lund, M. M. Linehan, N. Iijima, and A. Iwasaki,
“Cutting edge: plasmacytoid dendritic cells provide innate
immune protection against mucosal viral infection in situ,”
JournalofImmunology, vol.177,no.11,pp.7510–7514, 2006.
[76] K. Kawamura, N. Kadowaki, T. Kitawaki, and T. Uchiyama,
“Virus-stimulated plasmacytoid dendritic cells induce CD4+
cytotoxic regulatory T cells,” Blood, vol. 107, no. 3, pp. 1031–
1038, 2006.
[77] D. P. Barr, G. T. Belz, P. C. Reading et al., “A role for
plasmacytoid dendritic cells in the rapid IL-18-dependent
activation of NK cells following HSV-1 infection,” European
Journal of Immunology, vol. 37, no. 5, pp. 1334–1342, 2007.
[78] G. Gerlini, G. Mariotti, B. Bianchi, and N. Pimpinelli,
“Massive recruitment of type I interferon producing plas-
macytoid dendritic cells in varicella skin lesions,” Journal of
Investigative Dermatology, vol. 126, no. 2, pp. 507–509, 2006.
[79] J. H. Huch, A. L. Cunningham, A. M. Arvin et al., “Impact of
varicella-zoster virus on dendritic cell subsets in human skin
during natural infection,” Journal of Virology, vol. 84, no. 8,
pp. 4060–4072, 2010.
[80] H. Donaghy, L. Bosnjak, A. N. Harman et al., “Role for
plasmacytoid dendritic cells in the immune control of
recurrent human herpes simplex virus infection,” Journal of
Virology, vol. 83, no. 4, pp. 1952–1961, 2009.
[ 8 1 ]N .J .M e g j u g o r a c ,E .S .J a c o b s ,A .G .I z a g u i r r e ,T .C .G e o r g e ,
G. Gupta, and P. Fitzgerald-Bocarsly, “Image-based study of
interferongenic interactions between plasmacytoid dendritic
cells and HSV-infected monocyte-derived dendritic cells,”
Immunological Investigations, vol. 36, no. 5-6, pp. 739–761,
2007.
[82] N. A. Kittan, A. Bergua, S. Haupt et al., “Impaired plasma-
cytoid dendritic cell innate immune responses in patients
with herpes virus-associated acute retinal necrosis,” Journal
of Immunology, vol. 179, no. 6, pp. 4219–4230, 2007.
[83] J. A. Villadangos and L. Young, “Antigen-presentation prop-
erties of plasmacytoid dendritic cells,” Immunity, vol. 29, no.
3, pp. 352–361, 2008.
[84] W. Barchet, M. Cella, and M. Colonna, “Plasmacytoid
dendritic cells—virus experts of innate immunity,” Seminars
in Immunology, vol. 17, no. 4, pp. 253–261, 2005.
[85] R. Cabez´ o n ,J .S i n t e s ,L .L l i n ` as, and D. Benitez-Ribas,
“Analysis of HLDA9 mAbs on plasmacytoid dendritic cells,”
Immunology Letters, vol. 134, no. 2, pp. 167–173, 2011.
[86] P. Fitzgerald-Bocarsly and D. Feng, “The role of type I
interferon production by dendritic cells in host defense,”
Biochimie, vol. 89, no. 6-7, pp. 843–855, 2007.
[87] P. Schuster, N. Donhauser, K. Pritschet et al., “Co-ordinated
regulation of plasmacytoid dendritic cell surface recep-
tors upon stimulation with herpes simplex virus type 1,”
Immunology, vol. 129, no. 2, pp. 234–247, 2010.
[88] M. Swiecki and M. Colonna, “Unraveling the functions of
plasmacytoid dendritic cells during viral infections, autoim-
munity, and tolerance,” Immunological Reviews, vol. 234, no.
1, pp. 142–162, 2010.
[89] B. Moser and M. Brandes, “γδ T cells: an alternative type of
professional APC,” Trends in Immunology,v o l .2 7 ,n o .3 ,p p .
112–118, 2006.
[90] N. Kohrgruber, M. Gr¨ oger, P. Meraner et al., “Plasmacytoid
dendritic cell recruitment by immobilized CXCR3 ligands,”
JournalofImmunology, vol.173,no.11,pp.6592–6602, 2004.
[91] H. Yoneyama, K. Matsuno, Y. Zhang et al., “Evidence for
recruitment of plasmacytoid dendritic cell precursors to
inﬂamed lymph nodes through high endothelial venules,”
International Immunology, vol. 16, no. 7, pp. 915–928, 2004.
[ 9 2 ]G .d el aR o s a ,N .L o n g o ,J .L .R o d r ´ ıguez-Fern´ andez et al.,
“Migration of human blood dendritic cells across endothe-
lial cell monolayers: adhesion molecules and chemokines
involved in subset-speciﬁc transmigration,” Journal of Leuko-
cyte Biology, vol. 73, no. 5, pp. 639–649, 2003.
[93] A. Dzionek, A. Fuchs, P. Schmidt et al., “BDCA-2, BDCA-3,
and BDCA-4: three markers for distinct subsets of dendritic
cellsinhumanperipheralblood,”JournalofImmunology,vol.
165, no. 11, pp. 6037–6046, 2000.
[94] A. Dzionek, Y. Sohma, J. Nagafune et al., “BDCA-2, a
novel plasmacytoid dendritic cell-speciﬁc type II C-type
lectin, mediates antigen capture and is a potent inhibitor of
interferon α/β induction,” Journal of Experimental Medicine,
vol. 194, no. 12, pp. 1823–1834, 2001.
[95] P. S. Jaehn, K. S. Zaenker, J. Schmitz, and A. Dzionek, “Func-
tional dichotomy of plasmacytoid dendritic cells: antigen-
speciﬁc activation of T cells versus production of type I
interferon,” European Journal of Immunology, vol. 38, no. 7,
pp. 1822–1832, 2008.
[96] S. L. Fanning, T. C. George, D. Feng et al., “Receptor cross-
linking on human plasmacytoid dendritic cells leads to the
regulation of IFN-α production,” Journal of Immunology, vol.
177, no. 9, pp. 5829–5839, 2006.
[97] U. B˚ ave, M. Magnusson, M. L. Eloranta, A. Perers, G. V.
Alm, and L. R¨ onnblom, “FcγRIIa is expressed on natural
IFN-α-producing cells (plasmacytoid dendritic cells) and is
required for the IFN-α production induced by apoptotic cells
combined with Lupus IgG,” Journal of Immunology, vol. 171,
no. 6, pp. 3296–3302, 2003.
[98] T. K. Means, E. Latz, F. Hayashi, M. R. Murali, D. T.
Golenbock, and A. D. Luster, “Human lupus autoantibody-
DNA complexes activate DCs through cooperation of CD32
and TLR9,” Journal of Clinical Investigation, vol. 115, no. 2,
pp. 407–417, 2005.
[ 9 9 ]K .L o c k ,J .Z h a n g ,J .L u ,S .H .L e e ,a n dP .R .C r o c k e r ,
“Expression of CD33-related siglecs on human mononuclearAdvances in Virology 11
phagocytes, monocyte-derived dendritic cells and plasmacy-
toid dendritic cells,” Immunobiology, vol. 209, no. 1-2, pp.
199–207, 2004.
[100] M. Cella, F. Facchetti, A. Lanzavecchia, and M. Colonna,
“Plasmacytoiddendriticcellsactivatedbyinﬂuenzavirusand
CD40L drive a potent T1 polarization,” Nature Immunology,
vol. 1, no. 4, pp. 305–310, 2000.
[101] M. Cella, D. Jarrossay, F. Faccheth et al., “Plasmacytoid
monocytes migrate to inﬂamed lymph nodes and produce
large amounts of type I interferon,” Nature Medicine, vol. 5,
no. 8, pp. 919–923, 1999.
[102] G. M. Venturi, L. Tu, T. Kadono et al., “Leukocyte migration
is regulated by L-selectin endoproteolytic release,” Immunity,
vol. 19, no. 5, pp. 713–724, 2003.
[103] G. Penna, S. Sozzani, and L. Adorini, “Cutting edge: selective
usage of chemokine receptors by plasmacytoid dendritic
cells,” Journal of Immunology, vol. 167, no. 4, pp. 1862–1866,
2001.
[104] M. Colonna, G. Trinchieri, and Y. J. Liu, “Plasmacytoid
dendritic cells in immunity,” Nature Immunology, vol. 5, no.
12, pp. 1219–1226, 2004.
[105] M. Falco, E. Marcenaro, E. Romeo et al., “Homophilic
interactionofNTBA,amemberoftheCD2molecularfamily:
induction of cytotoxicity and cytokine release in human NK
cells,” European Journal of Immunology, vol. 34, no. 6, pp.
1663–1672, 2004.
[106] R. M. Flaig, S. Stark, and C. Watzl, “Cutting edge: NTB-
A activates NK cell via homophilic interaction,” Journal of
Immunology, vol. 172, no. 11, pp. 6524–6527, 2004.
[107] S. Stark and C. Watzl, “2B4 (CD244), NTB-A and CRACC
(CS1) stimulate cytotoxicity but no proliferation in human
NK cells,” International Immunology, vol. 18, no. 2, pp. 241–
247, 2006.
[108] M. Mart´ ın, J. M. Del Valle, I. Saborit, and P. Engel, “Identi-
ﬁcation of Grb2 as a novel binding partner of the signaling
lymphocytic activation molecule-associated protein binding
receptor CD229,” Journal of Immunology, vol. 174, no. 10, pp.
5977–5986, 2005.
[109] P. A. Valdez, H. Wang, D. Seshasayee et al., “NTB-A, a new
activating receptor in T cells that regulates autoimmune
disease,” Journal of Biological Chemistry, vol. 279, no. 18, pp.
18662–18669, 2004.
[110] K. L. Jae, S. O. Mathew, S. V. Vaidya, P. R. Kumaresan, and
P. A. Mathew, “CS1 (CRACC, CD319) induces proliferation
and autocrine cytokine expression on human B lympho-
cytes,” Journal of Immunology, vol. 179, no. 7, pp. 4672–4678,
2007.
[111] S. Calpe, N. Wang, X. Romero et al., “The SLAM and
SAP gene families control innate and adaptive immune
responses,” Advances in Immunology, vol. 97, pp. 177–250,
2008.
[112] P. A. Duttagupta, A. C. Boesteanu, and P. D. Katsikis,
“CostimulationsignalsformemoryCD8+ Tcellsduringviral
infections,”CriticalReviewsinImmunology,v ol.29,no .6,pp .
469–486, 2009.
[113] S. Hanabuchi, N. Watanabe, Y.-H. Wang et al., “Human
plasmacytoid predendritic cells activate NK cells through
glucocorticoid-induced tumor necrosis factor receptor-
ligand (GITRL),” Blood, vol. 107, no. 9, pp. 3617–3623, 2006.
[114] A.Marschner,S.Rothenfusser,V.Hornungetal.,“CpGODN
enhance antigen-speciﬁc NKT cell activation via plasmacy-
toiddendriticcells,”EuropeanJournalofImmunology,vol.35,
no. 8, pp. 2347–2357, 2005.
[115] J. Diana, T. Griseri, S. Lagaye et al., “NKT cell-plasmacytoid
dendriticcellcooperationviaOX40controlsviralinfectionin
a tissue-speciﬁc manner,” Immunity, vol. 30, no. 2, pp. 289–
299, 2009.
[116] J. Shaw, Y. H. Wang, T. Ito, K. Arima, and Y. J. Liu,
“Plasmacytoid dendritic cells regulate B-cell growth and
diﬀerentiation via CD70,” Blood, vol. 115, no. 15, pp. 3051–
3057, 2010.
[117] T. Ito, M. Yang, Y. H. Wang et al., “Plasmacytoid dendritic
cells prime IL-10-producing T regulatory cells by inducible
costimulator ligand,” Journal of Experimental Medicine, vol.
204, no. 1, pp. 105–115, 2007.
[118] E. A. Moseman, X. Liang, A. J. Dawson et al., “Human
plasmacytoid dendritic cells activated by CpG oligodeoxynu-
cleotides induce the generation of CD4+CD25+ regulatory T
cells,” Journal of Immunology, vol. 173, no. 7, pp. 4433–4442,
2004.
[119] M. Gilliet and Y. J. Liu, “Generation of human CD8
T regulatory cells by CD40 ligand-activated plasmacytoid
dendritic cells,” Journal of Experimental Medicine, vol. 195,
no. 6, pp. 695–704, 2002.
[120] X. Romero, N. Zapater, M. Calvo et al., “CD229 (Ly9)
lymphocyte cell surface receptor interacts homophilically
through its N-terminal domain and relocalizes to the
immunological synapse,” Journal of Immunology, vol. 174,
no. 11, pp. 7033–7042, 2005.
[121] M. C. Montoya, D. Sancho, G. Bonello et al., “Role of ICAM-
3 in the initial interaction of T lymphocytes and APCs,”
Nature Immunology, vol. 3, no. 2, pp. 159–168, 2002.
[122] A. Dzionek, Y. Inagaki, K. Okawa et al., “Plasmacytoid
dendritic cells: from speciﬁc surface markers to speciﬁc
cellular functions,” Human Immunology, vol. 63, no. 12, pp.
1133–1148, 2002.
[123] R. Tordjman, Y. Lepelletier, V. Lemarchandel et al., “A
neuronal receptor, neuropilin-I, is essential for the initiation
of the primary immune response,” Nature Immunology, vol.
3, no. 5, pp. 477–482, 2002.
[124] K. Crawford, A. Stark, B. Kitchens et al., “CD2 engagement
induces dendritic cell activation: implications for immune
surveillance and T-cell activation,” Blood, vol. 102, no. 5, pp.
1745–1752, 2003.
[125] M. Capasso, L. G. Durrant, M. Stacey, S. Gordon, J. Ramage,
and I. Spendlove, “Costimulation via CD55 on human CD4+
T cells mediated by CD97,” Journal of Immunology, vol. 177,
no. 2, pp. 1070–1077, 2006.
[126] M. Matmati, W. Pouwels, R. Van Bruggen et al., “The
human EGF-TM7 receptor EMR3 is a marker for mature
granulocytes,” Journal of Leukocyte Biology,v o l .8 1 ,n o .2 ,p p .
440–448, 2007.
[127] D. B. Rosen, W. Cao, D. T. Avery et al., “Functional
consequences of interactions between human NKR-P1A and
its ligand LLT1 expressed on activated dendritic cells and B
cells,” JournalofImmunology,vol.180,no.10,pp.6508–6517,
2008.
[128] L. Chaperot, A. Blum, O. Manches et al., “Virus or TLR
agonists induce TRAIL-mediated cytotoxic activity of plas-
macytoid dendritic cells,” Journal of Immunology, vol. 176,
no. 1, pp. 248–255, 2006.
[129] A. W. Hardy, D. R. Graham, G. M. Shearer, and J. P.
Herbeuval, “HIV turns plasmacytoid dendritic cells (pDC)
into TRAIL-expressing killer pDC and down-regulates HIV
coreceptors by Toll-like receptor 7-induced IFN-α,” Proceed-
ings of the National Academy of Sciences of the United States of
America, vol. 104, no. 44, pp. 17453–17458, 2007.12 Advances in Virology
[130] G. Stary, I. Klein, S. Kohlhofer et al., “Plasmacytoid dendritic
cells express TRAILand induce CD4 T-cell apoptosis in HIV-
1 viremic patients,” Blood, vol. 114, no. 18, pp. 3854–3863,
2009.
[131] T. Di Pucchio, B. Chatterjee, A. Smed-S¨ orensen et al., “Direct
proteasome-independent cross-presentation of viral antigen
by plasmacytoid dendritic cells on major histocompatibility
complex class I,” Nature Immunology, vol. 9, no. 5, pp. 551–
557, 2008.
[132] J. Mouri` es, G. Moron, G. Schlecht, N. Escriou, G. Dadaglio,
and C. Lederc, “Plasmacytoid dendritic cells eﬃciently cross-
prime naive T cells in vivo after TLR activation,” Blood, vol.
112, no. 9, pp. 3713–3722, 2008.
[133] A. Fuchs, M. Cella, T. Kondo, and M. Colonna, “Paradoxic
inhibition of human natural interferon-producing cells by
the activating receptor NKp44,” Blood, vol. 106, no. 6, pp.
2076–2082, 2005.
[134] P. Rautenberg, L. Granˇ ciˇ cova, J. Hillenkamp, B. N¨ olle, J. B.
Roider, and H. Fickenscher, “Acute retinal necrosis from the
virologist’s perspective,” Ophthalmologe, vol. 106, no. 12, pp.
1065–1073, 2009.
[135] A. Gandorfer and S. Thurau, “Acute retinal necrosis,” Oph-
thalmologe, vol. 106, no. 8, pp. 751–760, 2009.
[136] U. Pleyer and S. Winterhalter, “Diagnosic and therapeutic
aspects of herpes virus associated uveitis,” Klinische Monats-
blatter fur Augenheilkunde, vol. 227, no. 5, pp. 407–412, 2010.
[137] J. Hillenkamp, B. N¨ olle, C. Bruns, P. Rautenberg, H. Ficken-
scher, and J. Roider, “Acute retinal necrosis: clinical features,
early vitrectomy, and outcomes,” Ophthalmology, vol. 116,
no. 10, pp. 1971–1975.e2, 2009.
[138] J. Hillenkamp, B. Nolle, P. Rautenberg, H. Fickenscher, and J.
Roider, “Acute retinal necrosis: clinical features and therapy
options,” Ophthalmologe, vol. 106, no. 12, pp. 1058–1064,
2009.
[139] M. T. Witmer, P. R. Pavan, B. D. Fouraker, and G. A. Levy-
Clarke, “Acute retinal necrosis associated optic neuropathy,”
Acta Ophthalmologica. In press.
[140] R.N.VanGelder,J.L.Willig,G.N.Holland,andH.J.Kaplan,
“Herpes simplex virus type 2 as a cause of acute retinal
necrosis syndrome in young patients,” Ophthalmology, vol.
108, no. 5, pp. 869–876, 2001.
[141] T. H. C. Tran, D. Stanescu, L. Caspers-Velu et al., “Clinical
characteristics of acute HSV-2 retinal necrosis,” American
Journal of Ophthalmology, vol. 137, no. 5, pp. 872–879, 2004.
[142] J. B. Ganatra, D. Chandler, C. Santos, B. Kuppermann, and
T. P. Margolis, “Viral causes of the acute retinal necrosis
syndrome,” American Journal of Ophthalmology, vol. 129, no.
2, pp. 166–172, 2000.
[143] J. Lund, A. Sato, S. Akira, R. Medzhitov, and A. Iwasaki,
“Toll-likereceptor9-mediatedrecognitionofHerpessimplex
virus-2 by plasmacytoid dendritic cells,” Journal of Experi-
mental Medicine, vol. 198, no. 3, pp. 513–520, 2003.
[144] G. K. Lima, G. P. Zolini, D. S. Mansur et al., “Toll-Like
Receptor (TLR) 2 and TLR9 expressed in trigeminal ganglia
are critical to viral control during herpes simplex virus 1
infection,” American Journal of Pathology, vol. 177, no. 5, pp.
2433–2445, 2010.
[145] L. N. Sørensen, L. S. Reinert, L. Malmgaard, C. Bartholdy,
A. R. Thomsen, and S. R. Paludan, “TLR2 and TLR9
synergistically control herpes simplex virus infection in the
brain,” Journal of Immunology, vol. 181, no. 12, pp. 8604–
8612, 2008.
[146] V. D. Menachery and D. A. Leib, “Control of herpes
simplex virus replication is mediated through an interferon
regulatory factor 3-dependent pathway,” Journal of Virology,
vol. 83, no. 23, pp. 12399–12406, 2009.
[147] V. D. Menachery, T. J. Pasieka, and D. A. Leib, “Interferon
regulatory factor 3-dependent pathways are critical for
control of herpes simplex virus type 1 central nervous system
infection,” Journal of Virology, vol. 84, no. 19, pp. 9685–9694,
2010.
[148] S. Dupuis, E. Jouanguy, S. Al-Hajjar et al., “Impaired
response to interferon-α/β and lethal viral disease in human
STAT1 deﬁciency,” Nature Genetics, vol. 33, no. 3, pp. 388–
391, 2003.
[149] S.Y.Zhang,E.Jouanguy,S.Ugolinietal.,“TLR3deﬁciencyin
patients with herpes simplex encephalitis,” Science, vol. 317,
no. 5844, pp. 1522–1527, 2007.
[150] A. Casrouge, S. Y. Zhang, C. Eidenschenk et al., “Herpes
simplex virus encephalitis in human UNC-93B deﬁciency,”
Science, vol. 314, no. 5797, pp. 308–312, 2006.
[151] K. Tabeta, K. Hoebe, E. M. Janssen et al., “The Unc93b1
mutation 3d disrupts exogenous antigen presentation and
signaling via Toll-like receptors 3, 7 and 9,” Nature Immunol-
ogy, vol. 7, no. 2, pp. 156–164, 2006.
[152] K. Gowrishankar, M. Steain, A. L. Cunningham et al.,
“Characterization of the host immune response in human
ganglia after herpes zoster,” Journal of Virology, vol. 84, no.
17, pp. 8861–8870, 2010.
[153] L. F. Kastrukoﬀ, A. S. Lau, F. Takei et al., “Redundancy in the
immune system restricts the spread of HSV-1 in the central
nervous system (CNS) of C57BL/6 mice,” Virology, vol. 400,
no. 2, pp. 248–258, 2010.